Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection

1

Posted: 2022-01-07 20:00:00
. 2021 Dec 30;S0264-410X(21)01665-0. doi: 10.1016/j.vaccine.2021.12.057. Online ahead of print. Affiliations Expand Affiliations 1 Department of Bioactive Material Sciences and Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Korea. 2 Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Korea. 3 Graduate School of Biotechnology, Kyung Hee University, Yongin 17104, Korea. 4 Department of Bioactive Material Sciences and Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Korea; Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Korea. Electronic address: yongsuk@jbnu.ac.kr. Item in Clipboard Ye Lin Yang et al. Vaccine. 2021. Show details Display options Display options Format . 2021 Dec 30;S0264-410X(21)01665-0. doi: 10.1016/j.vaccine.2021.12.057. Online ahead of print. Affiliations 1 Department of Bioactive Material Sciences and Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Korea. 2 Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Korea. 3 Graduate School of Biotechnology, Kyung Hee University, Yongin 17104, Korea. 4 Department of Bioactive Material Sciences and Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Korea; Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Korea. Electronic address: yongsuk@jbnu.ac.kr. Item in Clipboard CiteDisplay options Display options Format Abstract Middle East respiratory syndrome (MERS) is a threat to public health worldwide. A vaccine against the causative agent of MERS, MERS-coronavirus (MERS-CoV), is urgently needed. We previously identified a peptide ligand, Co4B, which can enhance antigen (Ag) delivery to the nasal mucosa and promote Ag-specific mucosal and systemic immune responses following intranasal immunization. MERS-CoV infects via the respiratory route; thus, we conjugated the Co4B ligand to the MERS-CoV spike protein receptor-binding domain (S-RBD), and used this to intranasally immunize C57BL/6 and human dipeptidyl peptidase 4-transgenic (hDPP4-Tg) mice. Ag-specific mucosal immunoglobulin (Ig) A and systemic IgG, together with virus-neutralizing activities, were highly induced in mice immunized with Co4B-conjugated S-RBD (S-RBD-Co4B) compared to those immunized with unconjugated S-RBD. Ag-specific T cell-mediated immunity was also induced in the spleen and lungs of mice intranasally immunized with S-RBD-Co4B. Intranasal immunization of hDPP4-Tg mice with S-RBD-Co4B reduced immune cell infiltration into the tissues of virus-challenged mice. Finally, S-RBD-Co4B-immunized mice exhibited were better protected against infection, more likely to survive, and exhibited less body weight loss. Collectively, our results suggest that S-RBD-Co4B could be used as an intranasal vaccine candidate against MERS-CoV infection. Keywords: Adjuvant; Ligand; MERS-CoV; Recombinant antigen; Vaccine. Copyright © 2021 Elsevier Ltd. All rights reserved. Conflict of interest statement Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
3月 31, 2021 bioassociates2

宿主遺伝子の発現を阻害するウイルスタンパク質(Nsp1)を標的としたCOVID-19治療アプローチの可能性

Nsp1と呼ばれるコロナウイルスタンパク質が遺伝子の活性をどのように抑制し、ウイルス複製を促進するかを特定する研究は、新しい COVID-19 治療への希望をもたらすものだ。 パンデミックが始まって以来、科学者らは、 COVID-19 の原因となるコロナウイルスであるSARS-CoV-2を理解するために果てしなく取り組んできた。ワクチンの登場にもかかわらず、ウイルスはまだ蔓延しており、代替療法を開発する必要がある。…

ゲスト 690人 と メンバー 9人 がオンラインです